Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 4/20 | 0.46 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.43 |
| ▸ | SRC | P12931 | 4/20 | 0.41 |
| ▸ | EGFR | P00533 | 3/20 | 0.41 |
| ▸ | ABL1 | P00519 | 2/20 | 0.40 |
| ▸ | ABL2 | P42684 | 2/20 | 0.40 |
| ▸ | TNF | P01375 | 2/20 | 0.40 |
| ▸ | LITAF | Q99732 | 2/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5597042 | 0.95 | HTR6 (0.43) | PIK3CAPIK3R1USP30SCN9AHPGDS | |
| SCHEMBL5596814 | 0.94 | MEN1 (0.42) | PIK3CAPIK3R1MEN1KMT2ANR3C1 | |
| SCHEMBL5596780 | 0.84 | TNF (0.43) | PIK3CAPIK3R1USP30SRCEGFR | |
| SCHEMBL5596878 | 0.82 | USP30 (0.47) | PIK3CAPIK3R1USP30SRCEGFR | |
| SCHEMBL5596809 | 0.81 | GPR119 (0.42) | MEN1KMT2ABCHEHTR6 | |
| SCHEMBL5596748 | 0.79 | HTR6 (0.41) | USP30TNFLITAFSCN9AHPGDS | |
| SCHEMBL5596329 | 0.78 | MEN1 (0.42) | TNFLITAFMEN1KMT2ANR3C1 | |
| SCHEMBL5596980 | 0.77 | USP30 (0.42) | PIK3CAPIK3R1USP30SCN9AHPGDS | |
| SCHEMBL5596750 | 0.76 | GPR119 (0.44) | USP30MEN1KMT2A | |
| SCHEMBL3940077 | 0.75 | USP30 (0.49) | USP30SRCEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1829876-A1 | NITROGENEOUS TRICYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-20060247266-A1 | Nitrogen-containing tricyclic compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247266-A1 | Nitrogen-containing tricyclic compounds | MYO1B, CHRM1, MYL12A | PIK3CA 1188/4885PIK3R1 189/4885USP30 3669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.